Floatz logo

513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Amxi-5001
Ovarian Cancer
AtlasMedx, IncorporatedP1/2CC (40)
Anti-Hcd70 Car Transduced Pbl
Ovarian Cancer
National Cancer Institute (NCI)P1/2CC (40)
Anti-Mesothelin Chimeric T Cell Receptor Transduced Peripheral Blood Lymphocytes
Ovarian Cancer
Weijia Fang, MDP1/2CC (40)
Apl-5125
Ovarian Cancer
Apollo Therapeutics LtdP1/2CC (40)
asp0739
Ovarian Cancer
Astellas Pharma Global Development, Inc.P1/2CC (40)
bi-1808
Ovarian Cancer
BioInvent International ABP1/2CC (40)
Camizestrant
Ovarian Cancer
AstraZenecaP1/2CC (40)
dc05f01
Ovarian Cancer
Heronova PharmaceuticalsP1/2CC (40)
Deoxycholic Acid
Ovarian Cancer
THERAPIM PTY LTDP1/2CC (40)
Dntgfβrii
Ovarian Cancer
University of ChicagoP1/2CC (40)
Dual-Target Antigen-Selected Car-Nk
Ovarian Cancer
Essen BiotechP1/2CC (40)
Ebnk-001
Ovarian Cancer
Essen BiotechP1/2CC (40)
Eb-Select Single-Target Car-Nk Cells
Ovarian Cancer
Essen BiotechP1/2CC (40)
Etx-19477
Ovarian Cancer
858 Therapeutics, Inc.P1/2CC (40)
fhb7h3.car-ts
Ovarian Cancer
The Affiliated Hospital of Xuzhou Medical UniversityP1/2CC (40)
Gamma1 Heavy Chain Humanized (1-450) [Vh (Homo Sapiens Ighv4-31*01 (89.9%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [9.7.13] (26-34.52-58.97-109)) (1-120) -Homo Sapiens Ighg1*01 (100%), G1M17,1 Ch1 K120, D12, L14 (Ch1 K120 (217) (121-218), Hinge 1-15 (219-233), Ch2 (234-343), Ch3 D12 (359), L14 (361) (344-448), Chs (449-450)) (121-450)], (223-214')-Disulfide With Kappa Light Chain Humanized (1'-214') [V-Kappa (Homo Sapiens Igkv1-12*01 (85.3%)-Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; Dimer (229-229'':232-232'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1,Glycoform Alfa
Ovarian Cancer
Cancer Research UKP1/2CC (40)
Gavo-Cel
Ovarian Cancer
TCR2 TherapeuticsP1/2CC (40)
gen1107
Ovarian Cancer
GenmabP1/2CC (40)
gpc3 cd146 car-t cells
Ovarian Cancer
Essen BiotechP1/2CC (40)
ilb2109
Ovarian Cancer
Innolake BiopharmP1/2CC (40)
Immunoglobulin G4 [237-Proline,242-Proline,243-Valine,244-Alanine,De-245-Glycine], Anti-(Human Mucin-16) (Human Monoclonal Regn5668 ?4-Chain), Disulfide With Human Monoclonal Regn5668 ?-Chain, (235?228?),(238?231?)-Bis(Disulfide) With Immunoglobulin G4 [230-Proline,235-Proline,236-Valine,237-Alanine,De-238-Glycine,436-Arginine,437-Phenylalanine,446-Proline] Anti-(Human Cd28 Antigen) (Human Monoclonal Regn5668 ?4-Chain) Disulfide With Human Monoclonal Regn5668 ?-Chain
Ovarian Cancer
Regeneron PharmaceuticalsP1/2CC (40)
Interleukin-15
Ovarian Cancer
Essen BiotechP1/2CC (40)
Inv-6452
Ovarian Cancer
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (40)
Inv-8989
Ovarian Cancer
Shenzhen Ionova Life Sciences Co., Ltd.P1/2CC (40)
INX315
Ovarian Cancer
Incyclix BioP1/2CC (40)
Lbl-024 For
Ovarian Cancer
Nanjing Leads Biolabs Co.,LtdP1/2CC (40)
Mdna11
Ovarian Cancer
Medicenna Therapeutics, Inc.P1/2CC (40)
Metr-Nk Cell
Ovarian Cancer
Anhui Provincial Cancer HospitalP1/2CC (40)
mt-4561
Ovarian Cancer
Tanabe Pharma America, Inc.P1/2CC (40)
Neoantigen Specific Tcr-T Cell Drug Product
Ovarian Cancer
Alaunos TherapeuticsP1/2CC (40)
ngm707
Ovarian Cancer
NGM Biopharmaceuticals, IncP1/2CC (40)
Ny-Eso-1 Tcr/ Dntgfβrii
Ovarian Cancer
University of ChicagoP1/2CC (40)
Oc-Eies
Ovarian Cancer
Shenzhen Geno-Immune Medical InstituteP1/2CC (40)
Oc-Igt Cells
Ovarian Cancer
Shenzhen Geno-Immune Medical InstituteP1/2CC (40)
Palacaparib
Ovarian Cancer
AstraZenecaP1/2CC (40)
Pasifolate Exatecan
Ovarian Cancer
Elucida OncologyP1/2CC (40)
Puxitatug Samrotecan
Ovarian Cancer
AstraZenecaP1/2CC (40)
ql2107
Ovarian Cancer
Qilu Pharmaceutical Co., Ltd.P1/2CC (40)
qls5132
Ovarian Cancer
Qilu Pharmaceutical Co., Ltd.P1/2CC (40)
Rezatapopt
Ovarian Cancer
PMV Pharmaceuticals, IncP1/2CC (40)
Sacituzumab
Ovarian Cancer
Icahn School of Medicine at Mount SinaiP1/2CC (40)
Saruparib
Ovarian Cancer
AstraZenecaP1/2CC (40)
SL-28
Ovarian Cancer
Second Life TherapeuticsP1/2CC (40)
Solnerstotug
Ovarian Cancer
Sensei Biotherapeutics, Inc.P1/2CC (40)
Solvatinib
Ovarian Cancer
Anhui Provincial Cancer HospitalP1/2CC (40)
Spedox-6
Ovarian Cancer
University of California, IrvineP1/2CC (40)
S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide}
Ovarian Cancer
BicycleTx LimitedP1/2CC (40)
t3011
Ovarian Cancer
ImmVira Pharma Co. LtdP1/2CC (40)
Tak-853
Ovarian Cancer
TakedaP1/2CC (40)
tc-510
Ovarian Cancer
TCR2 TherapeuticsP1/2CC (40)
Showing 301 to 350 of 513 assets
PreviousPage 7 of 11Next